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Abstract: BGP-15 is a new insulin sensitizer drug candidate, which was developed by Hungarian
researchers. In recent years, numerous research groups have studied its beneficial effects. It is effective
in the treatment of insulin resistance and it has protective effects in Duchenne muscular dystrophy,
diastolic dysfunction, tachycardia, heart failure, and atrial fibrillation, and it can alleviate cardiotoxicity.
BGP-15 exhibits chemoprotective properties in different cytostatic therapies, and has also proven to be
photoprotective. It can additionally have advantageous effects in mitochondrial-stress-related diseases.
Although the precise mechanism of the effect is still unknown to us, we know that the molecule is a PARP
inhibitor, chaperone co-inducer, reduces ROS production, and is able to remodel the organization of
cholesterol-rich membrane domains. In the following review, our aim was to summarize the investigated
molecular mechanisms and pharmacological effects of this potential API. The main objective was to
present the wide pharmacological potentials of this chemical agent.
Keywords: BGP-15; chaperone co-inducer; PARP inhibitor; insulin sensitizer
1. Introduction
BGP-15 was originally developed to treat insulin resistance by N-Gene Research Laboratories
Inc., however, many additional pharmaceutical effects have been revealed in the last few decades [1].
The BGP-15 compound was discovered while investigating heat shock proteins, which are essential in
the functioning of the immune system. This pharmacon seemed to be a promising therapeutic agent,
with several beneficial effects based on these experiments. When it was discovered, it was thought that
the molecule may be able to treat many diseases. The compound targets a well-known mechanism of
the human body; the stimulation of heat shock protein expression, which leads to an increased stress
response and thus increased energy supply in the cells [2]. BGP-15 is a versatile compound, and many
research groups are paying significant attention to the molecule and investigating its effects all around
the world. It has been reported to be safe and well tolerated [3]. It entered into clinical phase II trials
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for the indication of insulin resistance. [4]. The objective of this review is to summarize BGP-15’s
effects, and the experiments that have been performed to increase the knowledge about this active
pharmaceutical ingredient (API).
2. Chemical Properties
BGP-15 (C14H22N4O2·2HCl) is a nicotinic amidoxime derivate (Figure 1), (Z) (N′-(2-hydroxy
-3-(piperidin-1-yl)propoxy)-3-pyridine-carboximidamide), and a solid material. Its molecular weight is
351,272 g/mol. Its solubility in deionized water is 28 mg/mL at 25 ◦C [6,7]; BGP-15 is a small molecule
and its water solubility is good. Water solubility and molecular weight are always crucial points
in the case of formulation of a certain API. Based on these pieces of information, working with this
chemical agent—from a pharmaceutical technology aspect—is not problematic at all.
Figure 1. Chemical structure of BGP-15 [5].
3. Mechanisms of Effects
Several research groups are currently studying this molecule; however, the exact mechanisms
of its effects are still unknown to us. All of the beneficial effects of BGP-15 are based on or linked to
the following mechanisms (Figure 2):
• BGP-15 inhibits the acetylation of heat shock factor 1 (HSF-1), thus increasing heat shock protein
(HSP) induction. It is a co-inducer of Hsp72 [3].
• BGP-15 blocks JNK, an inflammatory cytokine, thus preventing JNK from inhibiting
the phosphorylation of the insulin receptor, which results in increased insulin sensitivity [8–10].
• BGP-15 is a poly (adenosine 5′-diphosphate)–ribose] polymerase 1 (PARP-1) inhibitor, and is
able to reduce mitochondrial ROS production as well. Pharmacological inhibition of PARP
and reducing the production of reactive oxygen species (ROS) can be effective in a wide selection
of diseases, by protecting the cells against death [11].
• BGP-15 increases AKT levels moderately, and AKT is a signaling factor in the insulin-signaling
pathway. This results in increased glucose uptake and the survival of the cells. AKT activation
causes the deactivation of GSK-3, thus the kinase inhibitory phosphorylation of HSF-1 will
decrease [8,9].
• BGP-15 activates Rac1, a signaling protein, which increases the level of H2O2. H2O2 acts
as a messenger and increases HSF-1, thus promoting HSP induction [8,9].
• BGP-15 is able to remodel lipid rafts and to increase membrane fluidity, which is important
because stiff membranes are limiting the cellular stress response [8,9,12,13].
BGP-15 inhibits JNK’s inhibitory effect on the insulin receptor, thus insulin sensitivity is improved.
BGP-15 blocks the PARP enzyme, which decreases cell death. BGP-15 is able to inhibit mitochondrial
ROS production, which also results better survival of cells. Moreover, BGP-15 increases AKT
phosphorylation, leading to GSK-3 deactivation, thus the inhibitory phosphorylation of HSF-1 will
decrease and HSP induction will increase. It also inhibits the acetylation of HSF-1, which results in
increased HSP activity. BGP-15 activates Rac 1, thus the H2O2 level will increase, which will activate
HSF-1 and induce HSP activity.
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Figure 2. Mechanisms of effects of BGP-15.
4. Pharmacology
BGP-15 has entered clinical trials in insulin resistance indication, but its effectiveness has
previously been demonstrated in various other diseases as well. The main indication for this
compound is the treatment of diabetes and insulin resistance [3,14]. It might also be an adjuvant in
the therapy of Duchenne muscular dystrophy (DMD) [15]. Moreover, BGP-15 can be a cardioprotective
agent in ischemia-reperfusion injury treatment [16], it improves diastolic dysfunction in diabetic
cardiomyopathy [17], and it can be effective in treating heart failure as well [18]. In addition, it is
proven to be neuroprotective in cisplatin or taxol-induced peripheral neuropathy [19], and is also
a promising photoprotective agent [20]. It additionally has protective effects in nephrotoxicity induced
by cisplatin [21]. Administration of BGP-15 also has potential in traumatic brain injury [22], and it
could be effective in the therapy of ventilation induced diaphragm dysfunction [23]. This molecule can
be efficient in oxidative-stress-related diseases as well [24].
As mentioned above, BGP-15 has various beneficial effects, but we know the most about its
insulin sensitizing effect. Some of the other beneficial effects require further investigation to expand
our knowledge and learn more about the API. There are many ongoing experiments, so other effects
and data are expected to be published in the future regarding BGP-15.
5. Preclinical Studies
In drug development, preclinical studies must be performed to estimate human responses
and extend the knowledge regarding the API before clinical studies can begin. They are usually
performed with the help of in vitro and in vivo tests [25]. In the series of investigations related to
BGP-15, research groups have selected different types of cell culture models and animal models,
which are summarized in this chapter.
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5.1. Cell Culture Models
MEF cells (mouse embryonic fibroblasts) were selected to investigate the effects of BGP-15 on
the heat shock response [26]. These fibroblasts were harvested from mice embryos and applied for
the examination of molecular mechanisms [27]. To determine Hsp72 effectiveness in the treatment of
obesity-induced insulin resistance, L6 myotubes were deployed [28]. This cell line is a suitable in vitro
model for the investigation of glucose uptake [29]. To evaluate the effect of BGP-15 on mitochondrial
fragmentation, WRL-68, C2C12, A549 and Sf9 cell cultures were maintained [30]. Mitochondrial ROS
production has also been studied on the WRL-68 cell line [24]. These HeLa derivatives can be a useful
model for the examination of hepatocyte function in vitro [31]. C2C12 cells are immortalized mouse
myoblast cells with the ability to quickly develop into skeletal or cardiac muscle cells [32]. A549 cells
are human lung adenocarcinoma cells that are commonly used as a type II pulmonary epithelial cell
model [33]. Sf9 are derived from the pupal ovarian tissue of Spodoptera frugiperda. This cell line is often
used because of its high-level protein expression [34]. Besides the WRL-68 cell line, mitochondrial ROS
production has also been studied using H9c2 and U-251 cells [24]. H9c2 cells are rat heart myoblasts,
and are often used to examine the metabolic activity of the heart [35]. U-251 MG cells are human
malignant glioma cells [36]. B16-F10 mouse melanoma cells were maintained to study the BGP-15
effect mechanism [37]. NRVM are neonatal rat ventricular myocytes originating from Sprague–Dawley
strain rats’ ventricles, and were used for the investigation of the therapeutic role of BGP-15 in heart
failure and atrial fibrillation [18].
5.2. Animal Models
Wistar rats are one of the most commonly used rodents for animal experiments. Several effects of
BGP-15 have been investigated using Wistar rats. The insulin sensitizer effect [14], the chemoprotective
action in cisplatin or taxol therapy [19], the cardioprotective effect in imatinib therapy [38], and its effect
in ischemia-reperfusion injury [11,16] have all been studied with the help of these rats. In a few cases,
only some of their organs have been used. For example, the cardioprotective action of the molecule has
been investigated with the help of the Langendorff heart perfusion system [11,16,38]. This is a suitable
and versatile in vitro model for different experiments carried out on smaller animals’ (rats, mice,
and rabbits) hearts [39].
There have been other types of rats used for the investigation of BGP-15. The effect of cardiovascular
(CV) complications caused by diabetes and the insulin sensitizing effect of the API have been studied
on Goto–Kakizaki rats [17]. These animals are one of the most commonly used rat models of type 2
diabetes mellitus. They display mild hyperglycemia and damaged glucose tolerance, while being
normotensive and non-obese [17]. Besides the insulin-sensitizing effect, the role of BGP-15 in
alleviating ventilation-induced diaphragm dysfunction has been examined on Sprague–Dawley
rats [40]. The advantage of these rats is their calmness and easy handling [41]. On Zucker obese rats,
the insulin sensitivity of BGP-15 has been investigated in combination with rimonabant [4]. These types
of rats are a suitable genetic model for studying obesity and hypertension. They are insulin resistant,
but not hyperglycemic [42].
The other commonly used small animals are mice. Several types of mice have been selected for
experiments relating to BGP-15.
The protective effect of BGP-15 in liver injury caused by acetaminophen has been investigated
on CD-1 mice [1]. These mice are a general model for safety and efficacy testing [43]. To test the role
of Hsp72 in the treatment of obesity-induced insulin resistance, leptin deficient (ob/ob) mice were
selected [44]. They are a suitable model of mild type 2 diabetes and obesity [45]. The efficacy of
BGP-15 in the therapy of Duchenne muscular dystrophy was tested on mdx and dko mice [15,46].
Although mdx mice (X-chromosome-linked DMD) have no functional dystrophin, unfortunately
the DMD phenotype is mild in comparison to the human disease. The dko (dystrophin–utrophin
double knockout) mice lack both utrophin and dystrophin, and this loss results in a much more severe
phenotype [47]. For the investigation of the photoprotective effect of the pharmacon, hairless mice
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were used (VAF/plus CRL: hr/hr BR); they have the obvious advantages of topical administration being
much easier, and the results being more visible and easier to detect [20].
The beneficial effect of BGP-15 has been investigated in PCOS, as an ER stress inhibitor [48],
in oxaliplatin therapy induced skeletal myopathy and ROS production [49], and in oxaliplatin induced
intestinal dysfunction [50]. The investigations were carried out on BALB/c mice. They are useful in
experiments for both immunology and cancer [51].
To study the protective effect of the pharmacon in cisplatin caused nephrotoxicity, NMRI CV1 mice
and BD2F1 mice were selected [21]. NMRI CV1 mice are models for toxicology, teratology, physiology,
and pharmacology [52]. BD2F1 mice bear syngeneic lymphoid tumors [51].
Hsp110 deficient mice have been used to investigate whether the induction of Hsp70/Hsp110 can
protect mice from traumatic brain injury [22].
The effect of BGP-15 on the contractile function and morphology of regenerating soleus muscles
was examined on CB6F1 mice [53]. These animals are ideal for transplantation research or monoclonal
antibody production [54].
For the assessment of the therapeutic potential of BGP-15 in heart failure (HF) and atrial fibrillation
(AF), two mouse models were used. Both develop HF over time and exhibit an increased susceptibility to
AF; they are the cardiac-specific dnPI3K-Mst1 Tg mice20 and the cardiac-specific MURC Tg mice40 [18].
The effect of BGP-15 on mitochondrial dysfunction in obese mothers’ oocytes was evaluated.
For this purpose, a mouse model of Alstrom syndrome was selected. This is a rare genetic disease
which causes hyperphagia, leading to obesity, hyperinsulinemia, and diabetes [55]. To study the effect
of BGP-15 in gestational diabetes, mellitus female C57BL/6 mice were involved in the study and mated
with non-diabetic male mice to cause pregnancy. Brown adipose tissue was removed at the end of
the 15th week [56].
For investigation of the insulin sensitizer effect of BGP-15, white New Zealand rabbits were
selected. Their main advantage is their quick growth rate [14].
For the assessment of the role of BGP-15 in the treatment of tachycardia, Drosophila melanogaster
was selected. These fruit flies have a pumping heart and 85% of their genes have human homologues,
and many of these genes are associated with human cardiac diseases such as heart failure, arrhythmias,
and cardiomyopathy [57]. All animal models and the outcome of the related experiments are
summarized in Table 1.
Table 1. Summary of the studied effects and diseases, with the help of animal models.
Animal Model Studied Effect or Disease
Wistar rats [11,14,16,19] insulin sensitizing effect, chemoprotective action, cardioprotective effect
Goto-Kakizaki rats [17] insulin sensitizing effect, diabetes caused CV complications
Sprague–Dawley rats [40] insulin sensitizing effect, the role of BGP-15 in alleviating ventilation-induceddiaphragm dysfunction
Zucker obese rats [4] insulin sensitizing effect in combination of rimonabant
CD-1 mice [1] liver injury
Leptin deficient (ob/ob) mice [44] testing the role of Hsp72 effective in the treatment of obesity-induced insulin resistance
mdx and dko mice [15,46] Duchenne muscular dystrophy
hairless mice (VAF/plus CRL: hr/hr BR) [20] photoprotective effect
BALB/c mice [48–50] PCOS, oxaliplatin therapy induced skeletal myopathy and intestinal dysfunction
NMRI CV1 mice and BD2F1 mice [21] cisplatin caused nephrotoxicity
Hsp110 deficient mice [22] traumatic brain injury
CB6F1 mice [53] effect of BGP-15 on the contractile function and morphology of regeneratingsoleus muscles
cardiac-specific dnPI3K-Mst1 Tg mice20
and cardiac-specific MURC Tg mice40 [18] heart failure
mouse model of Alstrom syndrome [55] mitochondrial dysfunction
C57BL/6 mice [56] gestational diabetes mellitus
white New Zealand rabbits [14] insulin sensitizing effect
Drosophila melanogaster [57] tachycardia
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6. Potential Effects
6.1. Cardiovascular Effects
BGP-15 shows several beneficial cardiovascular effects, and has been investigated and studied
in a wide range of pathological conditions in several disease models (Table 2). It has proven to
be a promising therapeutic cardioprotective agent in ischemic heart disease [11]. Szabados E. et al.
investigated the molecular mechanism by which BGP-15 can protect the heart from ischemia–reperfusion
injury in a Langendorff heart perfusion system. They found that PARP is an important target of BGP-15,
and BGP-15 decreases ROS levels and cell injury during ischemia–reperfusion [11].
Bombicz M. et al. investigated the effectiveness of BGP-15 in relieving cardiac dysfunction
on Goto–Kakizaki rats, and found that BGP-15 is able to repair diastolic dysfunction in diabetic
cardiomyopathy [17]. Sapra G. et al. evaluated the therapeutic potential of BGP-15 in a mouse model
which can develop heart failure and is susceptible to atrial fibrillation. They came to the conclusion
that it ameliorates cardiac function and reduces arrhythmic episodes for those who suffer from heart
failure and atrial fibrillation [18]. Zhang D. et al. treated Drosophila melanogaster with BGP-15 in
tachycardia indication, and according to their experiments, BGP-15 was able to protect the heart against
tachycardia [57].
Table 2. Summary of investigations related to the cardiovascular effects of BGP-15.
Main Effect Dose
Reconstruction of diastolic dysfunction [17] 10 mg/kg BGP-15, per os
100 mg/kg metformin, per os
Amelioration of cardiac function and reduction of arrhythmic episodes [18] 15 mg/kg BGP-15
50 µM BGP-15 on the cells
Endogenous HSP overexpression and protection against tachycardia remodeling [57] 1 mM BGP-15
Reduction of ROS levels and cell injury during ischemia–reperfusion [11] The medium contained 40 mg/L of BFP-15
6.2. The Effect of BGP-15 in Duchenne Muscular Dystrophy
BGP-15 has potential in Duchenne muscular dystrophy (DMD); it could be used as a beneficial
adjuvant to therapy since it is able to improve the condition of cardiac pathology, and it ameliorates
dystrophic pathology (Table 3) [15,46]. Gehrig S. M. et al. tested whether overexpression of Hsp72 in
dystrophic muscles would ameliorate SERCA function. They found that treatment of dystrophic mice
with BGP-15, a pharmacological co-inducer of HSP 72, improved the pathology of DMD and extended
the lifetime [15]. Kennedy T. L. et al. investigated whether treatment with BGP-15 was beneficial in
older mdx and dko mice when advanced pathology had already occurred. Based on the results of their
experiments, it appears to only be effective in the early stage of the disease. Thus, it can be concluded
that BGP-15 has a therapeutic window [46].
Table 3. Summary of the investigations related to the of BGP-15 in the therapy of DMD.
Main Effect Dose
Improvement of DMD pathology and extension of lifetime [15] 15 mg/kg per day, oral gavage
Improvement of cardiac pathology in DMD, but skeletal muscle
function was not improved in older mdx or dko mice [46] 15 mg/kg BGP-15
6.3. Chemo and Cytoprotective Effects of BGP-15
It has been proven that the pharmacon can protect myenteric neurons of Balb/c mice from
oxaliplatin, making it a useful addition in chemotherapy; it might relieve some of the serious
side-effects of cytostatics. McQuade R. M. et al. tested whether BGP-15 is able to alleviate intestinal
dysfunction and oxaliplatin-induced enteric neuropathy. They came to the conclusion that BGP-15 is
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able to improve oxidative stress and increase enteric neuronal survival. It alleviated oxaliplatin-induced
intestinal dysfunction [50]. Racz I. et al. investigated the effects of BGP-15 on antitumor activity
and nephrotoxicity of cisplatin. They proved that BGP-15 treatment prevented the development of
acute renal failure in NMRI CV1 mice caused by cisplatin treatment [21].
Sarszegi Zs. et al. tested how BGP-15 would affect imatinib-caused cardiotoxicity. They discovered
that the oxidative damage in the heart was reversible by administration of BGP-15 [38]. According
to Bárdos G. et al., BGP-15 is a promising drug that can reduce toxic side effects of taxol
and cisplatin [15]. This beneficial effect of BGP-15 does not compromise the antitumor activity
of the cytostatics [19,21,38,50]. The relevant experiments are summarized in Table 4.
Table 4. Summary of the performed investigations related to the aforementioned effects of BGP-15.
Main Effect Dose
Reduction of the toxic side effects of taxol and cisplatin without
compromising their antitumor effect [19]
50, 100, 200 mg/kg of BGP-15, per os, once daily throughout
the experiment
1.5 mg/kg cisplatin, intraperitoneally, once daily, for 5 days
5 mg/kg taxol, intraperitoneally, every other day for 10 days
Reversal of oxidative damage in the heart, caused by imatinib [38] 200 µM BGP-15
Prevention of the development of acute renal failure caused by cisplatin
treatment [21] 100, 200 mg/kg BGP-15 shortly before cisplatin treatment
Alleviation of oxaliplatin-induced intestinal dysfunction, which eased
the gastrointestinal side-effects of chemotherapy [50]
15 mg/kg BGP-15
3 mg/kg oxaliplatin
6.4. BGP-15’s Effect in Liver Injury
Nagy G. et al. investigated the effects of BGP-15 in acetaminophen-provoked hepatocellular injury
(Table 5). BGP-15 is able to attenuate the degree of paracetamol-induced cell death, which could be
an important effect considering the severity of the disease [1].
Table 5. Summary of the investigation related to the effect of BGP-15 in paracetamol-induced cell death.
Main Effect Dose
Prevention of translocation of AIF (apoptosis inducing factor)
and mitochondrial depolarization. [1]
10, 20, 100, 200 mg/kg BGP-15
450 mg/kg acetaminophen
6.5. Insulin Sensitizing Effect of BGP-15
The main indication of the molecule is that it is able to increase insulin sensitivity in an insulin
resistant state; moreover, it improves the insulin resistance caused by atypical antipsychotic drugs
(AAPD). Furthermore, it is able to prevent the metabolic side effects caused by AAPDs, and also
potentiates the insulin sensitizing effect of rimonabant (Table 6) [3,4,14,58–60].
Literáti-Nagy B. et al. tried to quantify and demonstrate the insulin sensitizing effect of
BGP-15. They found that both the 200 and 400 mg BGP-15 dose groups showed markedly increased
insulin sensitivity [3]. In another study Literáti-Nagy B. et al. investigated the effect of BGP-15 in
the treatment of olanzapine-caused metabolic side effects. According to the results, BGP-15 markedly
decreased olanzapine-induced insulin resistance [58]. In a later experiment, Literáti-Nagy B. et al.
evaluated the insulin sensitizing effect of BGP-15 alone, and compared it with metformin, rosiglitazone,
and glibenclamide. As an insulin sensitizer, BGP-15 produced better results than metformin and equaled
the effect of rosiglitazone. It also proved to be efficient in increasing insulin sensitivity in combination
with a sulfonylurea agent (glibenclamide). Treatment with different doses of BGP-15 showed the insulin
sensitizing effect in cholesterol-fed rabbits, but not in normal rabbits. The most effective dose was
20 mg/kg. These experiments confirmed that BGP-15 has a beneficial effect only in the insulin-resistant
state [14]. Literáti-Nagy Zs. et al. tested the insulin sensitizing effect of BGP-15 in combination with
rimonabant. They found that BGP-15 potentiates the insulin sensitizing effect of rimonabant; it occurs
at much lower doses than would be expected if the two drugs were administered alone [4].
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Table 6. Summary of the investigations related to the insulin sensitizing effect of BGP-15.
Main Effect Dose
Reduction of olanzapine-induced insulin resistance [58] 400 mg of BGP-15 or placebo for 17 days
5 mg of olanzapine for 3 days and 10 mg for 14 days
Increase of insulin sensitivity [3]
200 mg or 400 mg of BGP-15, or placebo once daily,
for 4 weeks
Production of better results than metformin and rosiglitazone
Increase of insulin sensitivity in combination with a sulfonylurea agent (glibenclamide)
Increase of insulin sensitizing effect in cholesterol-fed rabbits, but not in normal rabbits. [14]
5, 10, 20, 30, or 50 mg/kg of BGP-15 per os
2 mg/kg rosiglitazone per os
100 mg/kg metformin per os
1 mg/kg glibenclamide per os
Intensification of insulin sensitizing effect of rimonabant; [4]
10 mg/kg rimonabant
30 mg/kg rimonabant
3 mg/kg BGP-15
10 mg/kg BGP-15 for 5 days
6.6. Effects of BGP-15 in Skin Injury, TBI, and VIDD
Farkas B. et al. investigated the protective effect of BGP-15 against injuries caused by UV rays.
BGP-15 treatment markedly decreased the number of sunburn cells in UV radiation exposed skin;
BGP-15 has a DNA protective effect if applied topically [20]. Eroglu B. et al. examined whether those
drugs that increase Hsp70/Hsp110 levels are able to protect cells against traumatic brain injury (TBI).
Mice were subjected to TBI and then BGP-15 was applied. Hsp70/Hsp110 have a significant role in
neuronal survival after TBI, and the inducers of these heat shock proteins have beneficial effects in
the reduction of the pathological consequences of TBI, thus BGP-15 has potential in TBI as it helps
promote the survival of neurons [22]. Salah H. et al. assessed the therapeutic effects of BGP-15 on
ventilation-induced diaphragm dysfunction (VIDD). BGP-15 increased diaphragm muscle fiber force
generation capacity, thus decreasing the negative effects of mechanical ventilation on diaphragm
muscle function [23]. The relevant experiments are summarized in Table 7.
Table 7. Summary of the investigations related to the aforementioned effects of BGP-15.
Main Effect Dose
Decrease of the number of sunburn cells in UV radiation exposed skin
5–20% concentration of BGP-15 in the creamDNA protective effect if applied topically [20]
Beneficial effects in the reduction of the pathological consequences of TBI [22] 15 mg/kg BGP-15, per os
Increasing diaphragm muscle fiber force generation capacity. 40 mg/kg BGP-15 iv.
Decreasing the negative effects of mechanical ventilation on diaphragm muscle function [23]
6.7. Gynecological Diseases and ROS-Related and Inflammatory Diseases
Recently, it has been discovered that BGP-15 might be useful in gynecological diseases (Table 8).
Takahashi N. et al. investigated the effects of BGP-15 in the treatment of PCOS mice. BGP-15 treatment
reduced interstitial fibrosis and collagen deposition in the ovaries [48]. Xing B. et al. evaluated the changes
in glucose and lipid metabolism levels after activation of Hsp70 with BGP-15. According to the results,
BGP-15 was able to significantly reduce abnormal post-natal weight gain [56].
Table 8. Summary of the investigations related to effects of BGP-15 in gynecological diseases.
Main Effect Dose
Reduction of interstitial fibrosis and collagen deposition in the ovaries [48] 3 mg/100g of body weight (BGP-15)
Reduction of abnormal weight gain after pregnancy [56] 100 mg/kg BGP-15
Prevention of ROS-related and inflammatory disease progression [24] 50 µM BGP-15
Sumegi K. et al. tested whether the protective effects of BGP-15 arise in connection with reducing
mitochondrial ROS production and through preserving mitochondrial integrity. According to their
results, BGP-15 exhibits protective effects against the progression of ROS-related and inflammatory
diseases by decreasing mitochondrial ROS production [24].
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More details about the experiments mentioned in the chapter “Potential Effects” can be found in
the Supplementary Materials.
7. Aspects of Pharmaceutical Technology
BGP-15 is a versatile agent with many potential applications, and it can be administered both
internally and externally. Topical use has already been investigated, and in the future different types
of semisolid dosage forms could be developed and formulated to utilize its photoprotective effect.
Since it is a promising insulin sensitizer agent, it could revolutionize the current therapy for insulin
resistance and type 2 diabetes. This is a suitable pharmacon for an orally administered solid dosage
form. The cardioprotective effect is also promising and, besides the conventional tablets and capsules,
transdermal patches could be an interesting and useful addition to formulations of this pharmacon,
which could improve patient compliance.
8. Clinical Trials of BGP-15
BGP-15 is a novel drug candidate, and it is currently in phase II human clinical trials. Based on
the previous clinical trial entitled “Safety and Efficacy of BGP-15 in Patients With Type 2 Diabetes
Mellitus” sponsored by N-Gene Research Laboratories Inc., BGP-15 has proven to be effective and well
tolerated in insulin resistance and Type 2 Diabetes Mellitus, however, it cannot not currently available
on the market yet. Unfortunately, the main indication (Type 2 Diabetes Mellitus) needs to be revaluated,
since it has not been verified. Careful controlling of biostatistical calculation detected that the patient
number in the groups should be increased. Therefore, a clinical trial with greater patient numbers with
repeated biostatistical calculations should be designed and carried out in the future. Nevertheless,
new promising preclinical results emerged, and the efficacy of BGP-15 as a chaperone co-inducer was
reported in early contractile dysfunction [61]. Based on this article, a new clinical trial is ready to
be submitted regarding the indication of inappropriate sinus tachycardia, which, hopefully, will be
successful due to the appropriate design and the suitable number of patients [62].
9. Summary
BGP-15 is a promising and versatile molecule with many beneficial effects that have been discovered
over the last decade [3,4]. It exhibits insulin sensitizing properties [3,4,14,58–60], and protective effects
in Duchenne muscular dystrophy [15,46], diastolic dysfunction, tachycardia, heart failure, and atrial
fibrillation, and it can fend off cardiotoxic effects [11,17,18,57]. It has proven to be chemoprotective
in different cytostatic therapies, and photoprotective as well [19–21,38,50]. It can also be effective
in mitochondrial-stress-related diseases [24]. Although the exact mechanism of action has not been
elucidated, it has been certified that the molecule is a chaperone co-inducer, PARP inhibitor, reduces
ROS production, and it is able to increase membrane fluidity [3,8–11]. These modes of action may
explain why the pharmacon has so many beneficial effects. The effects and the connected therapeutic
possibilities are currently being investigated by many research groups all over the world.
If BGP-15 successfully passes clinical trials in the future, it could be therapeutically effective for
the treatment of many diseases. In this review, many potential pharmacological effects of BGP-15 were
presented. Based on these pharmacological profiles, it could be registered as an original medicine;
however, the determination of a specific indication field is needed. Further human clinical trials might
certify the effective role of BGP-15 in a different medical treatment.
Supplementary Materials: The following are available online at http://www.mdpi.com/1420-3049/25/2/429/s1.
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to the insulin sensitizing effect of BGP-15. Table S6: Summary of the investigations related to the effects of
BGP-15 in skin injury, TBI, and VIDD. Table S7: Summary of the investigations related to effects of BGP-15 in
gynecological diseases.
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